ClinicalTrials.gg
CompletedNCT03400163Updated Feb 26, 2021Results posted

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of BMS-986036 and Placebo in Non-Alcoholic Steatohepatitis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled May 2015, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Bristol-Myers Squibb.

Enrollment
11th of 11
3 · median 40
Started
2015
with 1 other
Phase 2
6 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 3rd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)

03

Conditions studied

  • Non-Alcoholic Steatohepatitis

Keywords

  • First Line Therapy
  • NASH
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Male or female between 21 and 75 years old
  • (BMI) of 25 or more

Exclusion criteria

Exclusion Criteria:

  • Chronic Liver disease other than NASH
  • Uncontrolled diabetes
  • Any major surgery within 6 weeks of screening
  • Unable to self-administer under the skin injections
  • Any bone trauma, fracture or bone surgery within 8 weeks of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Treatment Group D:

    Administered as specified on specified days

    Drug: BMS-986036

  • Placebo comparator
    Treatment Group E:

    Administered as specified on specified days

    Drug: Placebo

Interventions

  • BMS-986036 20 mg QD

  • DrugPlacebo

    Placebo QD

06

What researchers measure

Primary outcomes

  1. Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16

    The mean change in percent hepatic fat fraction (%) by MRI from baseline to Week 16 was assessed for each arm. A longitudinal repeated measures analysis was used to analyze the change in hepatic fat fraction (%) at Week 16 from baseline in the treated population who have both a baseline and at least one post-baseline measurement.

    Time frame: From Day 1 to Day 112

  2. Number of Participants With Adverse Events (AEs)

    The number of participants with on-study AEs was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  3. Number of Participants With Serious Adverse Events (SAEs)

    The number of participants with on-study SAEs was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  4. Number of Participants With Injection Site Reactions

    The number of participants with on-study injection site reactions was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  5. Number of Participants With Adverse Events Leading to Discontinuation

    The number of participants with on-study AEs leading to discontinuation was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  6. Number of Deaths

    The number of deaths was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  7. Number of Participants With Marked Laboratory Abnormalities

    The number of participants whose worst toxicity grade increased from baseline to grade 3 or 4 (Toxicity Scale: DAIDS Version 1.0) is reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  8. Number of Participants With Vital Sign Abnormalities

    The number of participants with out-of-range vital signs noted during interim or final vital sign assessments was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  9. Number of Participants With Electrocardiogram (ECG) Abnormalities

    The number of participants with out-of-range ECG intervals observed during interim or final electrocardiogram assessments was reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  10. Number of Participants With Physical Examination Abnormalities

    The number of participants with abnormalities observed during interim or final physical examination assessments is reported for each arm.

    Time frame: From first dose to date of last dose plus 30 days

  11. Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)

    The mean percent change in bone mineral density from baseline to day 112 reported for each arm.

    Time frame: From Day 1 to Day 112

Secondary outcomes

  1. Geometric Mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112

    The observed serum concentration of BMS-986036 before the next dose is administered (pre-dose concentration) was assessed for both C-terminal intact and total molecule. Geometric means are presented for each arm.

    Time frame: From Day 1 to Day 112

  2. Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142

    Participants were monitored for antibodies to study medication using a validated ADA homogenous bridge assay with BMS-986036 and electrochemical luminescence detection. The number of treated participants with positive Anti-BMS-986036 antibody titers up to Day 142 with regards to baseline was reported for each arm.

    Time frame: From Day 1 to Day 142

  3. Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142

    Participants were monitored for antibodies to FGF21 using a validated homogenous bridge assay with Met-FGF21 (recombinant produced) and electrochemical luminescence detection. The number of treated participants with positive Anti-FGF21 antibody titers up to Day 142 with regards to baseline was reported for each arm.

    Time frame: From Day 1 to Day 142

07

Results

Posted Feb 19, 2020

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneBMS-986036 20 mg QDPlacebo 20 mg QD
Started12
Completed12
Not completed00
Follow-up Period
Participant flow — Follow-up Period
MilestoneBMS-986036 20 mg QDPlacebo 20 mg QD
Started12
Completed12
Not completed00

Outcome measures

PrimaryMean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16

The mean change in percent hepatic fat fraction (%) by MRI from baseline to Week 16 was assessed for each arm. A longitudinal repeated measures analysis was used to analyze the change in hepatic fat fraction (%) at Week 16 from baseline in the treated population who have both a baseline and at least one post-baseline measurement.

Time frame:
From Day 1 to Day 112
Reported as:
Mean · percentage
Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16
percentageBMS-986036 20 mg QDPlacebo 20 mg QD
Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16NA (NA to NA)NA (NA to NA)
PrimaryNumber of Participants With Adverse Events (AEs)

The number of participants with on-study AEs was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Adverse Events (AEs)NANA
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

The number of participants with on-study SAEs was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Serious Adverse Events (SAEs)NANA
PrimaryNumber of Participants With Injection Site Reactions

The number of participants with on-study injection site reactions was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Injection Site Reactions
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Injection Site BruisingNANA
Injection Site ErythemaNANA
Injection Site ReactionNANA
Injection Site PainNANA
Injection Site RashNANA
Injection Site SwellingNANA
PrimaryNumber of Participants With Adverse Events Leading to Discontinuation

The number of participants with on-study AEs leading to discontinuation was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Adverse Events Leading to DiscontinuationNANA
PrimaryNumber of Deaths

The number of deaths was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Deaths
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of DeathsNANA
PrimaryNumber of Participants With Marked Laboratory Abnormalities

The number of participants whose worst toxicity grade increased from baseline to grade 3 or 4 (Toxicity Scale: DAIDS Version 1.0) is reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Alanine Aminotransferase (ALT)NANA
Glucose, Fasting - highNANA
PrimaryNumber of Participants With Vital Sign Abnormalities

The number of participants with out-of-range vital signs noted during interim or final vital sign assessments was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Vital Sign Abnormalities
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Vital Sign AbnormalitiesNANA
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

The number of participants with out-of-range ECG intervals observed during interim or final electrocardiogram assessments was reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
PR > 200 msecNANA
QRS > 120 msecNANA
QT > 500 msecNANA
QTcF > 450 msecNANA
QT change from baseline > 30 msecNANA
QTcF change from baseline > 30 msecNANA
PrimaryNumber of Participants With Physical Examination Abnormalities

The number of participants with abnormalities observed during interim or final physical examination assessments is reported for each arm.

Time frame:
From first dose to date of last dose plus 30 days
Reported as:
Number · Participants
Number of Participants With Physical Examination Abnormalities
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Physical Examination AbnormalitiesNANA
PrimaryMean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)

The mean percent change in bone mineral density from baseline to day 112 reported for each arm.

Time frame:
From Day 1 to Day 112
Reported as:
Mean · Percentage
Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)
PercentageBMS-986036 20 mg QDPlacebo 20 mg QD
Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)NA ± NANA ± NA
SecondaryGeometric Mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112

The observed serum concentration of BMS-986036 before the next dose is administered (pre-dose concentration) was assessed for both C-terminal intact and total molecule. Geometric means are presented for each arm.

Time frame:
From Day 1 to Day 112
Reported as:
Geometric mean · ng/mL
Geometric Mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112
ng/mLBMS-986036 20 mg QDPlacebo 20 mg QD
C-Terminal IntactNA ± NANA ± NA
TotalNA ± NANA ± NA
SecondaryNumber of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142

Participants were monitored for antibodies to study medication using a validated ADA homogenous bridge assay with BMS-986036 and electrochemical luminescence detection. The number of treated participants with positive Anti-BMS-986036 antibody titers up to Day 142 with regards to baseline was reported for each arm.

Time frame:
From Day 1 to Day 142
Reported as:
Number · Participants
Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142NANA
SecondaryNumber of Participants With Positive Anti-FGF21 Antibody Response at Day 142

Participants were monitored for antibodies to FGF21 using a validated homogenous bridge assay with Met-FGF21 (recombinant produced) and electrochemical luminescence detection. The number of treated participants with positive Anti-FGF21 antibody titers up to Day 142 with regards to baseline was reported for each arm.

Time frame:
From Day 1 to Day 142
Reported as:
Number · Participants
Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142
ParticipantsBMS-986036 20 mg QDPlacebo 20 mg QD
Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142NANA

Adverse events

Collected over Non-serious adverse events after first dose of study medication and within 7 days of last dose and serious adverse events after first dose of study medication and within 30 days of last dose (approximately 4 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986036 20 mg QD———
Placebo 20 mg QD———

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-986036 20 mg QDPlacebo 20 mg QDTotal
Mean35 ± NA49.5 ± 2.1244.67 ± 8.50
Age, Customized
Age, Customized(Participants)BMS-986036 20 mg QDPlacebo 20 mg QDTotal
< 65 years of age123
>= 65 years of age000
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986036 20 mg QDPlacebo 20 mg QDTotal
Female123
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986036 20 mg QDPlacebo 20 mg QDTotal
Hispanic or Latino112
Not Hispanic or Latino011
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS-986036 20 mg QDPlacebo 20 mg QDTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White123
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jan 2017, 20 months.

Results were first posted in Feb 2020, 3 years 1 month after primary completion. A results delay was requested in Jan 2018.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2018
First posted
Jan 17, 2018
StartActual
May 8, 2015
Primary completionActual
Jan 18, 2017
CompletionActual
Jun 19, 2017
Results delay requested
Jan 17, 2018
Results first posted
Feb 19, 2020
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03400163
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
May 8, 2015
Primary completion
Jan 18, 2017
Completion
Jun 19, 2017
Results posted
Feb 19, 2020
Last update
Feb 26, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegbelfermin

Start the discussion